Structure Therapeutics (NASDAQ:GPCR) Hits New 12-Month Low – Time to Sell?

Posted by Brian Himes on Oct 30th, 2026

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR – Get Free Report) reached a new 52-week low during trading on Wednesday. The company traded as low as $20.50 and last traded at $20.7660, with a volume of 174,301 shares. The stock had previously closed at $21.55.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on GPCR. Citizens Jmp reiterated a “market outperform” rating and issued a $110.00 target price on shares of Structure Therapeutics in a research report on Wednesday, September 9th. HC Wainwright restated a “buy” rating on shares of Structure Therapeutics in a research report on Wednesday, September 9th. Canaccord Genuity Group set a $111.00 price objective on shares of Structure Therapeutics in a research note on Friday, August 7th. Citigroup reissued a “market outperform” rating on shares of Structure Therapeutics in a research report on Friday, August 7th. Finally, Wall Street Zen cut shares of Structure Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 3rd. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Structure Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $110.91.

Get Our Latest Research Report on Structure Therapeutics

Structure Therapeutics Stock Performance

The company’s 50-day simple moving average is $34.01 and its 200-day simple moving average is $49.68.

Structure Therapeutics (NASDAQ:GPCR – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). As a group, equities analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -1.87 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Structure Therapeutics

Several hedge funds have recently modified their holdings of the stock. Wellington Management Group LLP lifted its holdings in shares of Structure Therapeutics by 1.6% in the 2nd quarter. Wellington Management Group LLP now owns 7,379,433 shares of the company’s stock valued at $396,054,000 after buying an additional 119,146 shares during the period. Janus Henderson Group PLC lifted its position in shares of Structure Therapeutics by 5.2% during the 1st quarter. Janus Henderson Group PLC now owns 5,354,981 shares of the company’s stock valued at $258,260,000 after acquiring an additional 264,833 shares during the period. Principal Financial Group Inc. increased its stake in Structure Therapeutics by 36.6% in the 1st quarter. Principal Financial Group Inc. now owns 1,753,764 shares of the company’s stock valued at $84,531,000 after purchasing an additional 469,554 shares in the last quarter. Orbimed Advisors LLC raised its holdings in Structure Therapeutics by 27.0% during the first quarter. Orbimed Advisors LLC now owns 1,475,403 shares of the company’s stock worth $71,114,000 after purchasing an additional 313,600 shares during the last quarter. Finally, Siren L.L.C. raised its stake in shares of Structure Therapeutics by 23.2% during the 1st quarter. Siren L.L.C. now owns 1,328,698 shares of the company’s stock worth $64,043,000 after buying an additional 250,000 shares during the last quarter. 91.78% of the stock is owned by institutional investors and hedge funds.

About Structure Therapeutics

(Get Free Report)

Structure Therapeutics (NASDAQ: GPCR) is a clinical-stage biopharmaceutical company developing oral small-molecule medicines for chronic metabolic diseases. The company uses structure-based drug discovery and focuses on G protein-coupled receptors (GPCRs), a broad class of drug targets involved in metabolic and cardiovascular processes.

Its lead product candidate is GSBR-1290, an investigational oral GLP-1 receptor agonist being developed for obesity and type 2 diabetes. Structure Therapeutics is also advancing additional discovery and preclinical programs intended to address metabolic and related chronic diseases.